Prosight Management’s ADC Therapeutics ADCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$31.1M Sell
8,300,000
-177,338
-2% -$699K 5.1% 8
2025
Q4
$29.9M Buy
8,477,338
+1,005,035
+13% +$4.08M 6.18% 4
2025
Q3
$29.9M Sell
7,472,303
-2,995,468
-29% -$9.44M 7.18% 3
2025
Q2
$28.1M Buy
10,467,771
+924,767
+10% +$1.95M 6.84% 4
2025
Q1
$13.5M Buy
9,543,004
+28,004
+0.3% +$47.6K 4.42% 8
2024
Q4
$18.9M Sell
9,515,000
-121,237
-1% -$317K 5.3% 6
2024
Q3
$30.4M Buy
9,636,237
+66,237
+0.7% +$209K 7.7% 1
2024
Q2
$30.2M Buy
9,570,000
+2,519,700
+36% +$10M 9.04% 2
2024
Q1
$31.7M Buy
7,050,300
+578,500
+9% +$2.13M 8.81% 2
2023
Q4
$10.7M Buy
6,471,800
+1,069,759
+20% +$987K 4.47% 8
2023
Q3
$4.85M Sell
5,402,041
-181,859
-3% -$242K 1.54% 22
2023
Q2
$12M Buy
5,583,900
+2,326,540
+71% +$5.23M 3.51% 12
2023
Q1
$6.35M Buy
3,257,360
+2,794,050
+603% +$10.3M 3.04% 13
2022
Q4
$1.78M Buy
463,310
+215,680
+87% +$862K 0.99% 25
2022
Q3
$1.19M Buy
+247,630
New +$1.79M 0.66% 32

Other funds holding ADCT